Results 31 to 40 of about 52,108 (298)
Treatment of thrombotic thrombocytopenic purpura
The review discusses approaches to treatment of congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome. In congenital TTP, plasma transfusions are sufficient. Such treatment options as plasma exchange, administration of clotting factor VIII concentrate, recombinant ADAMTS13, are also used.
Gennadii M. Galstyan+3 more
openaire +7 more sources
Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005 [PDF]
The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management
D. YOUNG+8 more
core +2 more sources
Thrombotic Thrombocytopenic Purpura in Dengue Fever
Thrombotic thrombocytopenic purpura is a rare but life threatening medical condition. Early recognition and treatment of thrombotic thrombocytopenic purpura is important especially in patients who do not present with the classic pentad to reduce the ...
Tze Yuan Tee, Rizna Abdul Cader
doaj
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao+7 more
doaj +1 more source
Inherited thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia accompanied by variable neurological dysfunction, renal failure and fever.[1][1] Lesions consist of vessel wall thickening (mainly arterioles ...
Miriam Galbusera+2 more
doaj +4 more sources
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. [PDF]
The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome.
Bõze, Tamás+9 more
core +1 more source
Background Incidences of immune thrombocytopenic purpura occur in 1 in every 1000–10,000 pregnancies accounting for 3% of all thrombocytopenic pregnancies.
Naser Al-Husban, Oqba Al-Kuran
doaj +1 more source
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody ...
L. Völker+7 more
semanticscholar +1 more source
Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. [PDF]
Plasma exchange (PEX) is a life-saving therapeutic procedure in patients with thrombotic thrombocytopaenic purpura (TTP) and other thrombotic microangiopathic anaemias (TMAs). However, it may be associated with significant complications, exacerbating the
Collier, D+5 more
core +2 more sources
Thrombotic thrombocytopenic purpura
This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the discovery in 1997 of ADAMTS-13 deficiency as a major risk factor for acute disease manifestation.
J. A. Kremer Hovinga+2 more
openaire +5 more sources